Literature DB >> 20631574

Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.

Paolo Mannelli, Kathi Peindl, Ashwin A Patkar, Li-Tzy Wu, Chi-Un Pae, David A Gorelick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20631574      PMCID： PMC3091262          DOI： 10.1097/JCP.0b013e3181e5c168

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  16 in total

1.  Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.

Authors:  Sandy Ghozland; Hans W D Matthes; Frederic Simonin; Dominique Filliol; Brigitte L Kieffer; Rafael Maldonado
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

2.  Ultra-low dose naltrexone enhances cannabinoid-induced antinociception.

Authors:  Jay Paquette; Mary C Olmstead; Mary Olmstead
Journal:  Behav Pharmacol       Date:  2005-12       Impact factor: 2.293

3.  Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons.

Authors:  Anna Lisa Muntoni; Giuliano Pillolla; Miriam Melis; Simona Perra; Gian Luigi Gessa; Marco Pistis
Journal:  Eur J Neurosci       Date:  2006-05       Impact factor: 3.386

4.  Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.

Authors:  Marcello Solinas; Leigh V Panlilio; Gianluigi Tanda; Alexandros Makriyannis; Stephanie A Matthews; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2005-11       Impact factor: 7.853

Review 5.  Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against.

Authors:  D H Epstein; K L Preston
Journal:  Addiction       Date:  2003-03       Impact factor: 6.526

6.  Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.

Authors:  Margaret Haney
Journal:  Neuropsychopharmacology       Date:  2006-11-08       Impact factor: 7.853

7.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

8.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

9.  Two new rating scales for opiate withdrawal.

Authors:  L Handelsman; K J Cochrane; M J Aronson; R Ness; K J Rubinstein; P D Kanof
Journal:  Am J Drug Alcohol Abuse       Date:  1987       Impact factor: 3.829

10.  Interaction between naltrexone and oral THC in heavy marijuana smokers.

Authors:  Margaret Haney; Adam Bisaga; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2002-12-19       Impact factor: 4.530
View more
  3 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

2.  Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.

Authors:  Sarah Sushchyk; Zheng-Xiong Xi; Jia Bei Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-02-22       Impact factor: 4.030

Review 3.  Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives.

Authors:  Cenk Tek
Journal:  Patient Prefer Adherence       Date:  2016-05-04       Impact factor: 2.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.